Wall Street and institutional equity analysts tracking Healwell AI (AIDX) maintain a 12-month consensus average price target hovering around 1.88 CAD, with individual high forecasts reaching up to 2.25 CAD and conservative low estimates anchored near 1.50 CAD. These projections imply substantial potential percentage upside relative to its current micro-cap trading levels, driven by anticipated commercial scale and margin expansions.